|
Delayed
Börse Stuttgart
03:15:21 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 44.40 EUR | 0.00% |
|
+1.83% | +6.73% |
| 08-20 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 08-20 | Cancer vaccines finally garner the spotlight |  |
| Market Cap | 76.95B 105B 89.89B 83.87B 145B 10,045B 147B 995B 388B 5,034B 394B 386B 16,667B | P/E 2026 * |
14.5x | P/E 2027 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 96.15B 131B 112B 105B 181B 12,552B 184B 1,243B 485B 6,290B 493B 482B 20,825B | EV / Sales 2026 * |
2.83x | EV / Sales 2027 * | 2.63x |
| Free-Float |
92.75% | Yield 2026 * |
3.62% | Yield 2027 * | 3.9% |
Last Transcript: GSK plc
| 1 week | +1.83% | ||
| Current month | -0.89% | ||
| 1 month | +1.37% | ||
| 3 months | +1.83% | ||
| 6 months | -12.08% | ||
| Current year | +6.73% |
| 1 week | 42.2 |  | 45.2 |
| 1 month | 42.2 | | 48.6 |
| 3 years | 28.8 | | 52 |
| 5 years | 28.8 | | 52 |
| 10 years | 27.4 | | 52 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +1.83% | +29.07% | +44.16% | 105B | |
| -2.81% | +2.93% | +76.40% | +127.73% | 1,109B | |
| -2.21% | +2.02% | +49.50% | +55.01% | 644B | |
| -1.56% | +4.39% | +25.19% | +74.39% | 463B | |
| -1.22% | +3.35% | +39.81% | +44.32% | 371B | |
| -0.89% | +2.27% | +21.74% | +39.13% | 301B | |
| -0.88% | +4.67% | -0.44% | +12.38% | 256B | |
| -1.95% | +3.80% | +46.31% | +65.66% | 234B | |
| +0.03% | +0.80% | -16.58% | -52.89% | 205B | |
| -2.82% | +3.84% | +20.81% | +89.04% | 178B | |
| Average | -1.58% | +3.00% | +29.18% | +49.89% | 417.9B | |
| Weighted average by Cap. | -1.90% | +3.26% | +42.35% | +69.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.94B 46.31B 39.65B 36.99B 63.78B 4,431B 65.04B 439B 171B 2,221B 174B 170B 7,351B | 35.54B 48.48B 41.51B 38.73B 66.78B 4,639B 68.09B 459B 179B 2,325B 182B 178B 7,697B |
| Net income | 5.44B 7.42B 6.35B 5.92B 10.21B 710B 10.42B 70.28B 27.4B 356B 27.84B 27.24B 1,177B | 6.48B 8.85B 7.57B 7.07B 12.18B 846B 12.42B 83.83B 32.68B 424B 33.21B 32.49B 1,404B |
| Net Debt | 19.2B 26.19B 22.43B 20.92B 36.08B 2,506B 36.79B 248B 96.77B 1,256B 98.35B 96.21B 4,158B | 16.37B 22.34B 19.12B 17.84B 30.77B 2,137B 31.37B 212B 82.52B 1,071B 83.87B 82.04B 3,546B |
| Date | Price | Change |
|---|---|---|
| 26-08-21 | €44.40 | 0.00% |
| 26-08-20 | €44.40 | -1.77% |
| 26-08-19 | €45.20 | +2.26% |
| 26-08-18 | €44.20 | +1.84% |
| 26-08-17 | €43.40 | +1.88% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS70 Stock
Select your edition
All financial news and data tailored to specific country editions
